Pages that link to "Q30300233"
Jump to navigation
Jump to search
The following pages link to Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. (Q30300233):
Displaying 28 items.
- Could there be light at the end of the tunnel? Mesocaval shunting for refractory esophageal varices in patients with contraindications to transjugular intrahepatic portosystemic shunt (Q26739786) (← links)
- NAFLD and liver transplantation: Current burden and expected challenges (Q30248646) (← links)
- Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? (Q30252463) (← links)
- Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. (Q30274723) (← links)
- Liver transplant recipients with portal vein thrombosis receiving an organ from a high-risk donor are at an increased risk for graft loss due to hepatic artery thrombosis. (Q30275773) (← links)
- Pre-transplant portal vein thrombosis is an independent risk factor for graft loss due to hepatic artery thrombosis in liver transplant recipients (Q30277088) (← links)
- Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis (Q30277946) (← links)
- Portal vein thrombosis in patients with cirrhosis (Q33647169) (← links)
- Autoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients: A UNOS database analysis (Q36024830) (← links)
- Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease (Q36333338) (← links)
- Decreased Portal Vein Velocity is Predictive of the Development of Portal Vein Thrombosis: a Matched Case-Control Study (Q38668946) (← links)
- The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans (Q38752520) (← links)
- Mesocaval Shunt Creation for Jejunal Variceal Bleeding with Chronic Portal Vein Thrombosis (Q47102152) (← links)
- Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery. (Q50616462) (← links)
- Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? (Q52584505) (← links)
- Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study. (Q53513180) (← links)
- Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis. (Q55342502) (← links)
- Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference (Q56336457) (← links)
- Nonalcoholic fatty liver disease- evidence for a thrombophilic state? (Q89464483) (← links)
- Anticoagulation in the cirrhotic patient (Q89624005) (← links)
- Hypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and Management (Q90388064) (← links)
- Management of Non-tumoral Portal Vein Thrombosis in Patients with Cirrhosis (Q90601597) (← links)
- MRI of atherosclerosis and fatty liver disease in cholesterol fed rabbits (Q90695207) (← links)
- Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH (Q92070614) (← links)
- Hyponatremia Is Protective Against the Development of Portal Vein Thrombosis in Patients Undergoing Liver Transplant (Q92531766) (← links)
- Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate (Q93184530) (← links)
- Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge (Q98612724) (← links)
- PRO: Portal Vein Thrombosis Impacts Liver Transplantation Outcomes (Q101457569) (← links)